

Special Issue

Advances in the Management of Peritoneal Surface Malignancies

Message from the Guest Editor

Peritoneal surface malignancies, whether primary or secondary, continue to be difficult to manage. Despite the fact that there have been significant successes in the treatment of hematologic-based metastases, the peritoneum surface remains relatively elusive due to a blood–peritoneal barrier. However, in combination with effective systemic therapies, progress has been made with the addition of cytoreductive surgery and hyperthermic intraperitoneal therapy (CRS-HIPEC). This Special Issue of *Cancers* aims to include original studies and reviews of the important topics in peritoneal surface malignancies and their treatment, including CRS-HIPEC and systemic therapy. The integration of surgery, systemic therapy, and other modalities will require cooperation between the various types of providers. Many in the field have strong opinions about the management of peritoneal surface malignancies, which could hinder progress. Providers in several fields need to remain open-minded. Finally, several studies have shown that only institutions with the appropriate resources and volume of cases should take on the more complex cases of peritoneal surface malignancies.

Guest Editor

Prof. Dr. Mazin Al-Kasspooles

Peritoneal Surface Malignancy Program, Division of Surgical Oncology, Department of Surgery, The University of Kansas Health System, Kansas City, MO 66160, USA

Deadline for manuscript submissions

closed (15 March 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/194263

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)